Vascular News and Research

RSS

Emboshield Pro safer in patients ineligible for standard surgical treatment of CAD

Placing a stent in a key artery in the neck is safer than ever in patients ineligible for the standard surgical treatment of carotid artery disease, according to a new study published online today in the Journal of Vascular Surgery.

12 Jan 2012

Excess salt stimulates production of adrenalin and causes hypertension

A review article by researchers at Boston University School of Medicine (BUSM) debunks the widely-believed concept that hypertension, or high blood pressure, is the result of excess salt causing an increased blood volume, exerting extra pressure on the arteries. Published online in the Journal of Hypertension, the study demonstrates that excess salt stimulates the sympathetic nervous system to produce adrenalin, causing artery constriction and hypertension.

12 Jan 2012

Damon Runyon Cancer Research Foundation names 18 new Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

11 Jan 2012

New possibilities for effective treatment of psoriasis

Researchers at Link-ping University in Sweden are now launching a plan to effectively treat psoriasis.

11 Jan 2012

Researchers use 3-D imaging to identify proteins involved in arterial stiffness

Human arteries - some smaller than a strand of hair - stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process.

10 Jan 2012

Insulin induces formation of new elastin in cultures of human aortic smooth muscle cells

New research reveals that insulin applied in therapeutic doses selectively stimulates the formation of new elastic fibers in cultures of human aortic smooth muscle cells.

10 Jan 2012

Study identifies netrin-1 as novel target for atherosclerosis

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries. The research, published online by Nature Immunology on January 8, 2012, explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, accumulate in artery plaques.

10 Jan 2012

Novel target in artery plaque identified as potential therapeutic intervention

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries.

9 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Scottsdale Healthcare is first in Arizona to perform TAVR procedure

Scottsdale Healthcare Osborn Medical Center is the first hospital in Arizona to perform a new nonsurgical heart valve replacement procedure, the Transcatheter Aortic Valve Replacement (TAVR). TAVR valves are inserted via a catheter through the femoral artery, without requiring open heart surgery.

6 Jan 2012

CRF sponsors Seventh International Conference on Cell Therapy for Cardiovascular Disease

The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation (CRF) is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.

5 Jan 2012

Positive results from ProFibrix Phase II Fibrocaps clinical trial

ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant reduction in mean time to hemostasis (TTH) and incidence of hemostasis at 3, 5 and 10 minutes, as compared to active control.

5 Jan 2012

IARS celebrates 90 years of support of anesthesia-related research

The International Anesthesia Research Society (IARS), the oldest professional society for anesthesiologists, originally founded as the National Anesthesia Research Society, celebrates 90 years of support of medical research in 2012.

5 Jan 2012

Cutera to purchase assets of IRIDEX' global aesthetic business

Cutera, Inc. and IRIDEX Corporation today announced that the companies have entered into a binding agreement for Cutera to purchase certain assets of IRIDEX' global aesthetic business for approximately $5.1 million.

3 Jan 2012

Adiponectin may play a role in development of all-cause dementia and AD in women

A hormone derived from visceral fat called adiponectin may play a role as a risk factor for development of all-cause dementia and Alzheimer disease (AD) in women, according to a study published Online First by the Archives of Neurology, one of the JAMA/Archives journals.

3 Jan 2012

Vascular News and Research

Emboshield Pro safer in patients ineligible for standard surgical treatment of CAD

Excess salt stimulates production of adrenalin and causes hypertension

Damon Runyon Cancer Research Foundation names 18 new Fellows

New possibilities for effective treatment of psoriasis

Researchers use 3-D imaging to identify proteins involved in arterial stiffness

Insulin induces formation of new elastin in cultures of human aortic smooth muscle cells

Study identifies netrin-1 as novel target for atherosclerosis

Novel target in artery plaque identified as potential therapeutic intervention

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Scottsdale Healthcare is first in Arizona to perform TAVR procedure

CRF sponsors Seventh International Conference on Cell Therapy for Cardiovascular Disease

Positive results from ProFibrix Phase II Fibrocaps clinical trial

IARS celebrates 90 years of support of anesthesia-related research

Cutera to purchase assets of IRIDEX' global aesthetic business

Adiponectin may play a role in development of all-cause dementia and AD in women

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Faulty lipid metabolism may cause MS, says forensic anthropologist

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News